Kyverna TherapeuticsKYTX +2.93%12 FCF Yield % is -29.31 as of Jun. 27, 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Kyverna Therapeutics ranks worse than 74.33% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kyverna Therapeutics FCF Yield % Related Terms
Kyverna Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Kyverna Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kyverna Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyverna Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Kyverna Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyverna Therapeutics (KYTX) has a FCF Yield % of -29.31 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kyverna Therapeutics and its competitors. According to the industry distribution chart, Kyverna Therapeutics ranks #1054 out of 1418 companies in the Biotechnology industry, placing it in the top 74.3%.
Is Kyverna Therapeutics' FCF Yield % too high?
Kyverna Therapeutics' current FCF Yield % is -29.31. Based on the distribution chart, Kyverna Therapeutics ranks #1054 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' FCF Yield % compare to FDMT and XOMA?
According to the Biotechnology industry distribution chart, Kyverna Therapeutics ranks #1054 out of 1418 companies for FCF Yield %. This places Kyverna Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current FCF Yield % is -29.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current FCF Yield % of -29.31. The current FCF Yield % is -29.31. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current FCF Yield % is -29.31 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score
Get the complete analysis for KYTX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYTX has been successfully added to your 
